Shots:

• Charles River to receive up front- up to $50M as development milestones/ program- up to $120M as commercial milestones and royalties on net sales of the developed products.
• Takeda to launch multiple integrated programs targeting its four core therapeutic areas (oncology- gastroenterology- neuroscience- and rare disease) and will get an option to advance the preclinical candidates via their clinical development pipeline
•  The agreement combines Charles’ drug discovery expertise and deep scientific bench with Takeda’s investments in human data and translation to deliver transformative therapies to the needy patients

Click here ­to­ read full press release/ article 

Ref: Businesswire | Image:Takeda